Statement by the President of the Government during his visit to the facilities of the biotechnology pharmaceutical company HIPRA.

Spain Pedro Sánchez · Prime Minister of Spain

11 April 2023 · HIPRA biotechnology pharmaceutical company facilities, Spain

Context
Sánchez visited HIPRA's facilities in Catalonia on April 11, 2023, to celebrate the European Medicines Agency's approval of the company's COVID-19 vaccine, Bivermax.
Main themes
HIPRA COVID-19 vaccine approval, biotechnology and pharmaceutical innovation, pandemic response in Spain, public health and vaccination success, science and research recognition, government support for healthcare workers, European Medicines Agency approval, COVID-19 pandemic lessons, civic responsibility and vaccine uptake, collaboration between public and private sectors
Duration
~16 min
54th percentile
Words
1,894
54th percentile
Sentences
69
45th percentile
Readability
40
36th percentile
Grade
14.4
70th percentile
Syntax
3.29
81st percentile
Vocabulary
2.12
30th percentile

Translated from Spanish

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 36%36%
  • Ceremonial 28%28%
  • Economic 17%17%
  • Geopolitical 10%10%
  • Technological 6%6%
  • Institutional 3%3%
  • Environmental 0%0%
  • Not in focus 0%

69 sentences in 30 paragraphs

Thank you very much, David, President and CEO of HIPRA. Minister of Health. General Director of HIPRA. Authorities, because the Government delegate is also here. Chus (María Jesús Lamas), President of the Spanish Agency for Medicines and Health Products. Workers of this company.

Friends, the truth is that I am excited because, as I remembered earlier, this is not the first time I visit these facilities; but, without a doubt, it is the most emotional and the most symbolic.

On March 30, as the director, the president, and CEO of the company recalled earlier, we witnessed a historic milestone in science and also in research in our country; and that is the final approval by the European Medicines Agency of the HIPRA vaccine, which will be marketed under the name Bivermax.

It is often said, with a certain degree of truth, that we sometimes abuse the term "historic" to refer to some events, many of them very successive and intense in recent times. However, I believe that this time that qualifier is more than deserved; not only because it represents a lot for research and science done here, in Catalonia, in Spain, in Europe, but also because of the emotional weight behind what we are celebrating today. And that is achieving this vaccine, the memory of everything we experienced in the face of a pandemic that we are only beginning to leave behind thanks to science.

That is why I want to strongly reinforce that public recognition from the Government of Spain to the workers of HIPRA, but also to the public servants of the AEMPS, of the Carlos III Institute, of the entire Ministry of Health, and also of the different Health Departments, in this case, of the Generalitat of Catalonia, because together we have made this reality possible, which not long ago was just a dream.

We always knew that it was there, in science, where our only hope would reside. If healthcare workers, with their heroic dedication, were our first line of defense, evidently, you and the scientists were the great asset to help us counterattack and overcome, in a way not definitive, but with a lot of strength, this COVID virus.

Today, when I recall those days, I think of all the decisions we had to make, very tough, unprecedented, difficult decisions, in the face of an enemy about which humanity knew almost nothing at that time.

We did things that, without a doubt, helped us defend ourselves until that moment when science gave us the answer: a state of alarm to limit mobility, to confine citizens and, therefore, to protect ourselves against the spread of a virus that was already among us; the push for unprecedented mechanisms to protect workers such as ERTEs or also ICOs, which protected more than four million people, especially recalling those aid mechanisms through ERTEs or from the mobilization of resources to manufacture masks, which we did not have in Spain and neither in Europe, to the ventilators - we had to confiscate the ventilators that were in bullrings because there was also no capacity to manufacture ventilators in our country - or even the design of a cautious escalation so that the return to activity would not undermine so many sacrifices.

I remember having spoken with different leaders. For example, with the President of South Korea, to know exactly how they had designed that escalation and to be able to start resuming daily activity by our fellow citizens.

We did all that while, of course, we were looking sideways at science and placing all our hope in places and spaces like this and in people like you - if you allow me to address you informally - in those of you who make research and knowledge not only a profession but a true vital passion.

Nothing illustrates that hope better than the exemplary response of Spanish society to the vaccination process. I think it is very important to highlight this. I remember having spoken with many European leaders over the past months and years, and they asked me how it is possible that in Spain we could achieve that response, that civic awareness, that commitment not only to people but also to the safety of our fellow citizens.

There are more than 41 million vaccinated people today in our country; 40.7% with a complete regimen. We are, along with Portugal - the Iberian Peninsula - the country in Europe with the highest vaccination rate, approaching 90%. It is not only a success but also a huge pride that says a lot about our society, because that percentage represents many things.

It represents, for example, the triumph of science over denialism, which has unfortunately also existed during this pandemic. It always exists when there are these scientific challenges that nature subjects us to. It is the thermometer that also measures the civic awareness of a mature society, but that is also supportive, which assumed the decision to get vaccinated as a civic duty, much beyond protecting oneself personally and collectively protecting all our fellow citizens. And, therefore, it is an extraordinary reason, one more reason to feel a legitimate pride in our country.

We were alongside HIPRA from the very beginning. David mentioned it earlier, through the Spanish Agency for Medicines and Health Products, the Carlos III Institute, the public hospitals, which have also done so much to be able to carry out all these trials in a timely manner, even in record time, and, logically, also the cooperation between administrations and the Ministry of Health and the Ministry of Science and Innovation.

And the final result, I believe, is an extraordinary example of public-private collaboration, which we have been talking about for years and which I believe will be very necessary for many of the transformations and transitions that our society is currently undergoing. Between a large company in this case, present on four continents, with 2,400 workers, a leader in the development of biotechnological vaccines, and an administration that wanted to be complicit from the beginning in undertaking and making science a strategic bet for our country.

And that complicity has something very important that I would like to highlight before the media. It is the European dimension, the European dimension of what we are celebrating today, with the signing of the framework contract for the supply of 250 million doses to 14 member countries. And as a result of this, Spain materialized on November 8, by agreement of the Council of Ministers, the purchase of 3.2 million doses with an investment of 31 million euros.

Doses of a vaccine, by the way, as David mentioned earlier, of excellent quality. Ease of preservation, efficacy, versatility to adapt to new variants, in short, a formidable triumph for a company that dedicates, I remember having seen it also on my first visit, 10% of its turnover to R&D and 16% of its staff also to this same task.

That is why, friends, you recalled it earlier, David, three years ago we went through an experience that I would qualify as traumatic. I think I have said it many times: both the pandemic and the war in Ukraine, in Europe, therefore, in Western society and particularly in European society, have opened our eyes. Perhaps we were living a sort of fiction of being immune to wars or pandemics that we saw on other continents, but that passed by the European continent. That was not real, we are seeing it again today.

But in any case, we lived that traumatic experience and now with a certain distance and a certain desire to turn the page, I believe there are some lessons that we must not forget from everything that has happened to us in these three complex and difficult years.

The first, I believe, is evident. That weakening public health is the worst decision any ruler can make because, sooner or later, the bill ends up being paid, and moreover, it is not done from a conjunctural point of view, but also structural. Today we have, fortunately, more healthcare workers and a strategic reserve, the Minister of Health told me. Also with better equipment. But we must continue to strengthen our public health system.

The second is that providing ourselves with greater strategic autonomy is a priority. It is for Spain, without a doubt, and it is for Europe in multiple areas, but also in the health field.

Today we have the impetus of the European funds that we fought so hard to obtain from the Government of Spain three years ago. And we have a medium and long-term vision of what reindustrialization means for our country to strengthen our own capabilities.

Strategic autonomy in the health field, as well as in technology, energy, semiconductors, and agro-industry, will be one of the fundamental elements of the Spanish Presidency of the European Union in the next semester, the second semester of the year. And therefore, not doing it, not industrializing our country, our continent, not strengthening our strategic autonomy, only makes Europe a much more vulnerable continent in the face of future crises that will come, hopefully a long time from now, but they will come and we must be much better prepared than we were in 2020.

And the third conclusion or lesson we should draw, and I certainly keep it very much in mind, is that a country without science is a country without a future. A decade of cuts severely weakened our R&D system, opening a huge gap with the countries around us.

And closing that gap not only translates into more and better jobs, which is what we are seeing, but it is also something that has to do with an act of justice if you allow me to speak in these terms with those who are currently training in our universities and also in our vocational training centers. Because we owe it to ourselves as a country that no generation of researchers should ever have to seek outside what their land is unable to offer them.

And in that sense, I believe that the employment data known a week ago is a good proof of something that is changing, fortunately for the better in our country. In one year, affiliation in scientific and technical activities has grown by 9% and doubled, 18% if we talk about those under 30 years old. The same is true in other high value-added sectors.

That, I believe, is, and with that I conclude, the path we must follow, the lessons we must draw from this pandemic that is still present among us.

A path in which successful examples like that of this HIPRA vaccine help to tell the story of a country, of a community, that rises to adversity. That knows it is capable of innovating and creating, and that looks to the future with confidence to continue advancing.

Therefore, dear friends, it is an honor for me, and I must tell you again, as I said at the beginning of my speech, that I am very excited to move along that path hand in hand with a great company like HIPRA.

So, congratulations. Thank you from the bottom of my heart to those who have made this milestone possible. A milestone, with all the letters and all the merit, historic. Congratulations and, again, thank you.